ECSP15022505A - Producto de comicronización que comprende un modulador selectivo del receptor de progesterona - Google Patents

Producto de comicronización que comprende un modulador selectivo del receptor de progesterona

Info

Publication number
ECSP15022505A
ECSP15022505A ECIEPI201522505A ECPI201522505A ECSP15022505A EC SP15022505 A ECSP15022505 A EC SP15022505A EC IEPI201522505 A ECIEPI201522505 A EC IEPI201522505A EC PI201522505 A ECPI201522505 A EC PI201522505A EC SP15022505 A ECSP15022505 A EC SP15022505A
Authority
EC
Ecuador
Prior art keywords
comychronization
product including
progesterone receptor
selective modulator
product
Prior art date
Application number
ECIEPI201522505A
Other languages
English (en)
Inventor
Jérôme Hecq
Pierre-Yves Juvin
Aude Colin
Florian Battung
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of ECSP15022505A publication Critical patent/ECSP15022505A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)

Abstract

El objeto de la presente invención es un producto de comicronización que comprende: un ingrediente activo seleccionado del grupo que consiste en moduladores selectivos de los receptores de progesterona, metabolitos de los mismos y mezclas de los mismos, y un excipiente polimérico basado en N-vinil-2-pirrolidona. La invención también se refiere a una composición farmacéutica que comprende dicho producto de comicronización y a los usos terapéuticos de la misma.
ECIEPI201522505A 2012-11-08 2015-06-05 Producto de comicronización que comprende un modulador selectivo del receptor de progesterona ECSP15022505A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1260605A FR2997628B1 (fr) 2012-11-08 2012-11-08 Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone

Publications (1)

Publication Number Publication Date
ECSP15022505A true ECSP15022505A (es) 2016-01-29

Family

ID=47714259

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201522505A ECSP15022505A (es) 2012-11-08 2015-06-05 Producto de comicronización que comprende un modulador selectivo del receptor de progesterona

Country Status (22)

Country Link
US (1) US20150258118A1 (es)
EP (1) EP2916823B1 (es)
JP (1) JP2015536969A (es)
CN (1) CN105073098B (es)
CR (1) CR20150298A (es)
CY (1) CY1118884T1 (es)
DK (1) DK2916823T3 (es)
EA (1) EA029643B1 (es)
EC (1) ECSP15022505A (es)
ES (1) ES2625012T3 (es)
FR (1) FR2997628B1 (es)
GE (1) GEP201706648B (es)
HR (1) HRP20170686T1 (es)
LT (1) LT2916823T (es)
MD (1) MD4546C1 (es)
PL (1) PL2916823T3 (es)
PT (1) PT2916823T (es)
RS (1) RS55956B1 (es)
SI (1) SI2916823T1 (es)
SM (1) SMT201700237T1 (es)
UA (1) UA115573C2 (es)
WO (1) WO2014072647A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106265533A (zh) * 2016-10-10 2017-01-04 朱隆娅 一种阿德呋啉颗粒剂及其制备方法
FR3060389B1 (fr) * 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
WO2023033900A1 (en) 2021-09-06 2023-03-09 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
ES2212912B1 (es) * 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US8865200B2 (en) 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
AU2007327707B2 (en) * 2006-10-24 2012-07-12 Allergan pharmaceuticals International Ltd. Compositions and methods for suppressing endometrial proliferation
EA200970646A1 (ru) * 2006-12-28 2009-12-30 Репрос Терапьютикс Инк. Способы и составы для улучшения биодоступности антипрогестинов
JP2008169135A (ja) * 2007-01-11 2008-07-24 Takada Seiyaku Kk グリメピリド組成物の製造方法
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
BRPI1014035A2 (pt) 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
EP2535114A4 (en) * 2009-11-13 2015-11-18 Moriroku Chemicals Company Ltd FINE POWDER MANUFACTURING METHOD AND FINE POWDER PRODUCED BY THIS METHOD
FR2988610B1 (fr) * 2012-03-30 2014-10-31 Effik Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
CN102871977A (zh) * 2012-10-19 2013-01-16 北京紫竹药业有限公司 醋酸优力司特分散片及其制备方法

Also Published As

Publication number Publication date
UA115573C2 (uk) 2017-11-27
MD4546B1 (ro) 2018-01-31
EA029643B1 (ru) 2018-04-30
FR2997628B1 (fr) 2015-01-16
MD4546C1 (ro) 2019-03-31
LT2916823T (lt) 2017-07-25
JP2015536969A (ja) 2015-12-24
MD4546B9 (ro) 2018-08-31
HRP20170686T1 (hr) 2017-09-08
PL2916823T3 (pl) 2017-08-31
CN105073098B (zh) 2019-02-19
ES2625012T3 (es) 2017-07-18
EA201500514A1 (ru) 2015-09-30
SMT201700237T1 (it) 2017-07-18
SI2916823T1 (sl) 2017-08-31
CR20150298A (es) 2015-08-14
PT2916823T (pt) 2017-05-22
CN105073098A (zh) 2015-11-18
EP2916823A1 (fr) 2015-09-16
DK2916823T3 (en) 2017-05-15
RS55956B1 (sr) 2017-09-29
EP2916823B1 (fr) 2017-02-15
US20150258118A1 (en) 2015-09-17
GEP201706648B (en) 2017-03-27
WO2014072647A1 (fr) 2014-05-15
CY1118884T1 (el) 2018-01-10
MD20150054A2 (ro) 2015-10-31
FR2997628A1 (fr) 2014-05-09

Similar Documents

Publication Publication Date Title
NI201500076A (es) Dispersión sólida de un modulador selectivo de los receptores de progesterona.
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
UY35073A (es) Derivados de pirrolidinona como moduladores de GPR119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2019000115A1 (es) Compuestos y métodos para la modulación de smn2.
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX385357B (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
ECSP15022505A (es) Producto de comicronización que comprende un modulador selectivo del receptor de progesterona
CR20190007A (es) Composiciones farmacéuticas sólidas y formas de dosificación que comprenden aceites.
CL2014001928A1 (es) Compuestos derivados de espiro[biciclo[3.1.0]hexano-4,1’-ciclopropano], agonistas del receptor mglu2/3; y composicion farmaceutica que los comprende.
BR112017024356A2 (pt) clonidina e/ou derivados de clonidina para uso na prevenção de lesão na pele resultante de radioterapia
CL2011002316A1 (es) Compuestos derivados de furopirimidinona, moduladores de receptores trpa1; composicion farmaceutica; y uso en el tratamiento del dolor.